Best Vaccine Full Blast To

The latest treatment from Vertex Trikafta was approved by the FDA last October, and is applicable to 90 of global CF patients.

However, if theres a bright spot in all this, its biotech stocks.

Even those that arent directly working on a Covid-related solution look more attractive.

Besides the entire industry getting more attention than usual, investors know theyre less at risk of a consumer spending crunch that could hit tech companies like Apple ( NASDAQ: AAPL ).

Even so, that would just be the start should their research pay off.

Accurate and fast testing for Covid-19 infections is critical to determining whether someone needs to be isolated andor hospitalized for treatment.

As the country begins to re-open, testing becomes even more critical as medical authorities monitor for potential second waves of the pandemic.

Best Vaccine Full Blast To

Thats over 6 million to date, with production going full blast to manufacture another 20 million tests just to keep up with current and short-term demand.

On March 26, the company announced its IBIO-200 vaccine candidate was being fast-tracked to pre-clinical immunization studies at Texas AM University Systems (TAMUS) laboratories.

The American biotech company has been focused on mRNA therapy modifying the bodys RNA to treat conditions including cancer, cardiovascular disease and infectious diseases.

Modernas mRNA-1273 is a candidate as a Covid-19 vaccine, and it has potential.

On May 18, the company announced positive results for Phase 1 testing of the vaccine, led by the National Institute of Health.

These trials showed the subjects had antibody levels at or above levels measured in recovered Covid-19 patients, without showing serious side effects.

BIIB stock tanked in March 2019, falling 29 in its worst day of trading ever, after news broke that it was ending trials for a blockbuster Alzheimers drug called Aducanumab.

And second, Aducanumab (the Alzheimers drug) is back in play.

The company announced new phase 3 clinical trials in January.

Those were subsequently pushed to the third quarter (news that the market didnt take kindly to), but the new clinical trials raise hope that the company has a winner in Aducanumab.

This biotech company was the first to get government approval for a coronavirus treatment.

Remdesivir may not be a miracle cure, but clinical trials show it has reduced the recovery time required for some patients.

With many hospitals facing bed shortages, anything that reduces the time Covid-19 patients spend there is a big win, and Gilead has donated 1.5 million vials of the drug.

If the success continues and remdesivir becomes a go-treatment for Covid-19, Piper Sandler analysts project it could generate up to 2 billion in revenue for Gilead in 2020 alone even after giving away those 1.5 million doses.

This biopharmaceutical company isnt focused on Covid-19 research.

Best Vaccine For Mac